Placebo (NNC0487-0111)

DRUG3 trials

Sponsors

Novo Nordisk A/S

Conditions

ObesityOverweight

Phase 1

A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With Obesity

CompletedNCT06049329

Novo Nordisk A/SObesity

Start: 2023-09-14End: 2023-12-15Updated: 2025-03-05

A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants After 10 Days of Oral Dosing

CompletedNCT06820476

Novo Nordisk A/SObesity, Overweight

Start: 2025-02-09End: 2025-05-14Updated: 2025-08-20

Phase 2

A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin

CompletedNCT06064006

Novo Nordisk A/SObesity, Overweight

Start: 2023-09-15End: 2024-11-27Updated: 2025-11-19

Related Papers

Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study.

2025-06-2016 citations

2002-LB: Amycretin, a Novel, Unimolecular GLP-1 and Amylin Receptor Agonist—Results of a Phase 1b/2a Clinical Trial

Diabetes2025-06-13